[
  {
    "ts": null,
    "headline": "Lilly announces changes on board of directors",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024. In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities.",
    "url": "https://finnhub.io/api/news?id=1fcc3df14bbfcf73bf195b472ec93d673ab04184467c0144cf3144adb5dd84a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732051800,
      "headline": "Lilly announces changes on board of directors",
      "id": 131495031,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024. In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities.",
      "url": "https://finnhub.io/api/news?id=1fcc3df14bbfcf73bf195b472ec93d673ab04184467c0144cf3144adb5dd84a2"
    }
  },
  {
    "ts": null,
    "headline": "Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).",
    "url": "https://finnhub.io/api/news?id=e9358224ffccf1312be0145777ff3ce0ff8805ebfbacf6809660c3e4d1672db0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732051080,
      "headline": "Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley",
      "id": 131495032,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).",
      "url": "https://finnhub.io/api/news?id=e9358224ffccf1312be0145777ff3ce0ff8805ebfbacf6809660c3e4d1672db0"
    }
  },
  {
    "ts": null,
    "headline": "LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study",
    "summary": "Lilly's muvalaplin significantly reduces elevated Lp(a) levels compared to placebo in a phase II study",
    "url": "https://finnhub.io/api/news?id=c1ecaf75f3cc67d8c591c95ffe473e2bed3f8e4c4f6ee03caccaeee038faa45f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732046400,
      "headline": "LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study",
      "id": 131495033,
      "image": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's muvalaplin significantly reduces elevated Lp(a) levels compared to placebo in a phase II study",
      "url": "https://finnhub.io/api/news?id=c1ecaf75f3cc67d8c591c95ffe473e2bed3f8e4c4f6ee03caccaeee038faa45f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%",
    "summary": "On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a). Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues. Also Read: Eli Lilly’s Zepbound/Moun",
    "url": "https://finnhub.io/api/news?id=57db3393fb519bed90869a51ff6f6e7f5be85278797f72e4906720bf8b48fce9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732039700,
      "headline": "Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%",
      "id": 131495034,
      "image": "https://media.zenfs.com/en/Benzinga/0717dc3790a8f4821f30ae6a8069dc56",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a). Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues. Also Read: Eli Lilly’s Zepbound/Moun",
      "url": "https://finnhub.io/api/news?id=57db3393fb519bed90869a51ff6f6e7f5be85278797f72e4906720bf8b48fce9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and : Lilly announces changes on board of directors Form 8 K",
    "summary": "Lilly announces changes on board of directors INDIANAPOLIS, Nov. 19, 2024 -- Eli Lilly and Company announced today that it has elected Jon Moeller as a new member of...",
    "url": "https://finnhub.io/api/news?id=56e40adbbe4fd8b6e7254e8ca20a5f2d1338079f19cdcb2a88cbb803c9b8f6f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732035963,
      "headline": "Eli Lilly and : Lilly announces changes on board of directors Form 8 K",
      "id": 131492670,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Lilly announces changes on board of directors INDIANAPOLIS, Nov. 19, 2024 -- Eli Lilly and Company announced today that it has elected Jon Moeller as a new member of...",
      "url": "https://finnhub.io/api/news?id=56e40adbbe4fd8b6e7254e8ca20a5f2d1338079f19cdcb2a88cbb803c9b8f6f2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
    "summary": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=a3692759ee993c33486e5c5c7b54d7f6204ff4b05e17d51272d2bbdcecab8706",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732033980,
      "headline": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
      "id": 131505522,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=a3692759ee993c33486e5c5c7b54d7f6204ff4b05e17d51272d2bbdcecab8706"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund",
    "summary": "Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. All equity classes experienced good results in the third quarter. During the quarter, equity markets ended on a high note, with the S&P 500 achieving a 5.89% increase, bringing the full-year […]",
    "url": "https://finnhub.io/api/news?id=c245eb6a02b685523da615c3ef46a589d86fe34cd141a15a6d251c5088f0262f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732027316,
      "headline": "Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund",
      "id": 131480188,
      "image": "https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. All equity classes experienced good results in the third quarter. During the quarter, equity markets ended on a high note, with the S&P 500 achieving a 5.89% increase, bringing the full-year […]",
      "url": "https://finnhub.io/api/news?id=c245eb6a02b685523da615c3ef46a589d86fe34cd141a15a6d251c5088f0262f"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Large Cap Focus Growth V.I. Fund Q3 2024 Commentary",
    "summary": "BlackRock Large Cap Focus Growth V.I. Fund posted a return of 1.40% (Class I shares) for the third quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=9116d31307df9e71d5543493b51b32cf1960fbf53046d71ee1f0180545c2cb39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732023900,
      "headline": "BlackRock Large Cap Focus Growth V.I. Fund Q3 2024 Commentary",
      "id": 131482936,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Large Cap Focus Growth V.I. Fund posted a return of 1.40% (Class I shares) for the third quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=9116d31307df9e71d5543493b51b32cf1960fbf53046d71ee1f0180545c2cb39"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
    "summary": "Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
    "url": "https://finnhub.io/api/news?id=2ed99dd530505819b942a9efe0fb819c45bda3f2fd8c4cd0ba703de92786625c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732018645,
      "headline": "Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
      "id": 131470494,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
      "url": "https://finnhub.io/api/news?id=2ed99dd530505819b942a9efe0fb819c45bda3f2fd8c4cd0ba703de92786625c"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
    "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015683,
      "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
      "id": 131474886,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429734/image_107429734.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
      "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12"
    }
  },
  {
    "ts": null,
    "headline": "Employers Get Pressure to Pay for Drugs Like Wegovy",
    "summary": "Eli Lilly and Novo Nordisk representatives get facetime with companies in hopes they will cover their weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=4eb913bf5fa214bf1770d3a1725b227b5eabe370756ab70668fa5fce87abfe0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732012200,
      "headline": "Employers Get Pressure to Pay for Drugs Like Wegovy",
      "id": 131480190,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Novo Nordisk representatives get facetime with companies in hopes they will cover their weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=4eb913bf5fa214bf1770d3a1725b227b5eabe370756ab70668fa5fce87abfe0d"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For November",
    "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
    "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732007700,
      "headline": "IXJ: Healthcare Sector Dashboard For November",
      "id": 131471159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/688000635/image_688000635.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
      "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504"
    }
  },
  {
    "ts": null,
    "headline": "The Next Big Theme: November 2024",
    "summary": "OpenAI is collaborating with Broadcom and Taiwan Semiconductor to develop its first ever proprietary chip. Click to read.",
    "url": "https://finnhub.io/api/news?id=8273af3d0d573d83e106b3a1eeeb66e9525b0fd39f93b1b22b088e0171dbce5f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731996300,
      "headline": "The Next Big Theme: November 2024",
      "id": 131467911,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1763326395/image_1763326395.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "OpenAI is collaborating with Broadcom and Taiwan Semiconductor to develop its first ever proprietary chip. Click to read.",
      "url": "https://finnhub.io/api/news?id=8273af3d0d573d83e106b3a1eeeb66e9525b0fd39f93b1b22b088e0171dbce5f"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
    "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731993000,
      "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
      "id": 131467028,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1849023174/image_1849023174.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: positive trial results for muvalaplin in cardiology",
    "summary": "Eli Lilly announces positive results from a Phase 2 trial of muvalaplin, a selective oral inhibitor of lipoprotein [Lp], a genetic risk factor for cardiovascular disease. The study demonstrated...",
    "url": "https://finnhub.io/api/news?id=18e8fb6d30c10bb630284fb32c71af21d9529dd00eb76f759c9e5794bc56cf0d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731991455,
      "headline": "Eli Lilly: positive trial results for muvalaplin in cardiology",
      "id": 131466676,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announces positive results from a Phase 2 trial of muvalaplin, a selective oral inhibitor of lipoprotein [Lp], a genetic risk factor for cardiovascular disease. The study demonstrated...",
      "url": "https://finnhub.io/api/news?id=18e8fb6d30c10bb630284fb32c71af21d9529dd00eb76f759c9e5794bc56cf0d"
    }
  }
]